Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
UBS
Farmers Insurance
Moodys
Julphar
Johnson and Johnson
McKesson
Accenture

Generated: January 19, 2018

DrugPatentWatch Database Preview

Teva Pharms Intl Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS INTL, and when can generic versions of TEVA PHARMS INTL drugs launch?

TEVA PHARMS INTL has two approved drugs.

There are nine US patents protecting TEVA PHARMS INTL drugs on TEVA PHARMS INTL drugs in the past three years.

There are forty-four patent family members on TEVA PHARMS INTL drugs in nineteen countries.

Summary for Teva Pharms Intl
International Patents:44
US Patents:9
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Teva Pharms Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA PHARMS INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 10/26/2016
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 8/11/2008

Non-Orange Book US Patents for Teva Pharms Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Subscribe
8,877,245 Modified release dosage forms of skeletal muscle relaxants ➤ Subscribe
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Subscribe
7,169,774 Cephalotaxane derivatives and their processes of preparation and purification ➤ Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Teva Pharms Intl Drugs

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Cipla
QuintilesIMS
Daiichi Sankyo
Mallinckrodt
Cerilliant
Farmers Insurance
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot